

Blue Cross and Blue Shield of Alabama includes the following drugs in the Blue Advantage Part B Provider-Administered Drug Precertification Program. Precertification for these provider-administered drugs is required when administered in a provider's office, outpatient facility, or home health setting. Treatments indicated as Gene Therapy/Cellular Immunotherapy (+) require precertification when administered in any place of treatment.

Abecma+	Cimzia	Focinvez	Krystexxa	Perjeta
Abraxane	Cinqair	fosaprepitant	Kymriah+	Phesgo
Actemra IV	Cinryze	Fulphila	Kyprolis	Polivy
Adakveo	Cinvanti	Fulvestrant	Lamzede	Pombiliti
Adcetris	Columvi	Fusilev	Lemtrada	Portrazza
Adstiladrin+	Cortrophin	Fyarro	Lenmeldy	Poteligeo
Aduhelm	Cosentyx_IV	Fylnetra	Leqembi	Privigen
Adzynma	Crysvita	Gamifant	Leqvio	Probuphine
Akynzeo IV	Cutaquig	Gammagard	Leukine	Procrit
Aldurazyme	Cuvitru	Gammaked	Libtayo	Provenge
Alimta	Cyramza	Gammaplex	Loqtorz	Qalsody
Aloxi	Danyelza	Gamunex-C	Lucentis	Radicava
Alyglo	Darzalex	Gazyva	Lumizyme	Reblozyl
Alymsys	Darzalex Faspro	Gel-One	Lumoxiti	Releuko
Amondys 45	Daxxify	Gelsyn-3	Lunsumio	Retacrit
Amtagvi	Dextenza	Genvisc	Luxturna+	Rituxan Hycela
Amvuttra	Durolane	Givlaari	Lyfgenia+	Rituxan IV
Anktiva	Dysport	Granix	Macugen	Rivfloza
Aphexda	Elahere	Hemgenix+	Margenza	Roctavian+
Arzerra	Elaprase	Herceptin	Mepsevii	Rolvedon
Asceniv	Elelyso	Herceptin Hylecta	Monjuvi	Ruconest
Avastin*	Elevidys+	Hercessi	Monovisc	Rybrevent
Avzivi	Elfabrio	Herzuma	Mylotarg	Rystiggo
Bavencio	Elitek	Hizentra	Myobloc	Ryzneuta
Belrapzo	Elrexio	Hyalgan	Naglazyme	Saphnelo
Bendamustine	Elzonris	Hymovis	Neupogen	Sarclisa
Bendeka	Emend	Hyqvia	Nexviazyme	Scenesse
Benlysta IV	Empliciti	Ilaris	Nplate	Simponi Aria
Beovu	Enhertu	Ilumya	Nucala	Skyrizi IV
Beqvez	Enjaymo	Imdelltra	Nulibry	Skysona+
Berinert	Entyvio	Imfinzi	Ocrevus	Sodium Hyaluronate
Besponsa	Epkinly	Imjudo	Octagam	Soliris
Bivigam	Epogen	Imlygic	OmvoH	Spevigo
Blinicyto	Erbitux	Inflectra	Onpattro	Spinraza
bortezomib	Euflexxa	Ixempra	Ontruzant	Spravato
Botox	Evkeeza	Izervay	Opdivo	Stelara IV
Breyanzi+	Evomela	Jelmyto	Opdualag	Stimufend
Brineura	Exondys 51	Jemperli	Orencia IV	Sublocade
Briumvi	Eylea	Kadcyla	Oxlumo	Supartz
Byooviz	Eylea HD	Kalbitor	Paclitaxel Protein-Bound	Sustol
Carvykti+	Fabrazyme	Kanuma	Padcev	Susvimo
Casgevy+	Fasenra	Keytruda	Panzyga	Syfovre
Cerezyme	Faslodex	Khapzory	Pemfexy	Sylvant
Cimerli	Flebogamma	Kimmtrak	Pemtrexed	Synjojoynt

Talvey
Tecartus+
Tecentriq
Tecvayli
Tepezza
Testopel
Tevimbra
Tezspire
Tivdak
Tofidence
Treanda
Trelstar Depot
Triluron

Trivisc
Trodelvy
Trogarzo
Tyenne
Tyruko
Tysabri
Tzield
Udenyca
Ultomiris
Uplizna
Vabysmo
Vantas
Vectibix

Vegzelma
Velcade
Veopoz
Viltepso
Vimizim
Visco-3
Visudyne
Vivimusta
Vivitrol
Vpriv
Vyepiti
Vyjuvek+
Vyondys-53

Vyvgart
Vyxeos
Vyvgart Hytrulo
Wezlana
Winrevair
Xembify
Xenpozyme
Xeomin
Xiaflex
Xipere
Xolair
Yervoy
Yescarta+

Yondelis
Zaltrap
Zepzelca
Zoladex
Zolgensma+
Zynlonta
Zynteglo+
Zynyz

Drug Additions

Effective January 1, 2024:

Adzynma
Loqtorz
OmvoH
Ryzneuta
Wezlana

Drug Deletion

Effective January 1, 2024:

Truxima

Drug Additions

Effective February 1, 2024:

Alyglo
Avzivi
Casgevy+
Lyfgenia+

Drug Additions

Effective April 1, 2024:

Amtagvi

Drug Additions

Effective May 1, 2024:

Jubbonti
Wyost
Tyenne
Tevimbra
Lenmeldy
Winrevair

Drug Additions

Effective June 1, 2024:

Anktiva
Beqvez
Hercessi

Drug Deletions

Effective June 1, 2024:

Jubbonti
Ogivri
Prolia
Wyost
Xgeva

Drug Addition

Effective July 1, 2024:

Imdelltra

*Precertification required for oncology uses only.

Product names are the property of their respective owners. This list is updated monthly and is subject to change without notice.

Online policies can be found at [AlabamaBlue.com/Providers/Policies](https://www.alabamablue.com/providers/policies).